Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Linagliptin

FDA-approved product (tablet, oral), marketed as Linagliptin, Tradjenta.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Linagliptin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dipeptidyl peptidase 4 (dpp-4) inhibitors
FDA pharmacologic class
Dipeptidyl Peptidase 4 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Linagliptin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Linagliptin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal Insufficiency

    NCT07786571 · start 2026-12-01

    Registered record
    Registry ID
    NCT07786571
    Conditions
    Type 2 Diabetes Mellitus (T2DM); Chronic Renal Insufficiency; Chronic Kidney Disease (Stages 3b-5); Glucose Homeostasis
    Interventions
    Dorzagliatin; Linagliptin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2029-07-01
    Enrolment
    206

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus (T2DM); Chronic Renal Insufficiency; Chronic Kidney Disease (Stages 3b-5); Glucose Homeostasis
    InterventionDorzagliatin; Linagliptin
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Glycemic Variability of Combination Therapies in T2DM

    NCT07442006 · start 2025-10-29

    Registered record
    Registry ID
    NCT07442006
    Conditions
    Type 2 Diabetes Mellitus (T2DM)
    Interventions
    Empagliflozin/Metformin; Anagliptin; Metformin; Empagliflozin/Linagliptin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-10-29
    Completion
    2027-03-31
    Enrolment
    178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus (T2DM)
    InterventionEmpagliflozin/Metformin; Anagliptin; Metformin; Empagliflozin/Linagliptin
    PhasePhase 4
    Registry statusRecruiting

  • Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.

    NCT07019012 · start 2025-07-30

    Registered record
    Registry ID
    NCT07019012
    Conditions
    T2DM
    Interventions
    SGLT2i+Metformin+Cofrogliptin; SGLT2i+Metformin+Linagliptin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-07-30
    Completion
    2026-12-30
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionT2DM
    InterventionSGLT2i+Metformin+Cofrogliptin; SGLT2i+Metformin+Linagliptin
    PhasePhase 4
    Registry statusRecruiting

  • Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD

    NCT06449833 · start 2024-06

    Registered record
    Registry ID
    NCT06449833
    Conditions
    Type2 Diabetes Mellitus; Nonalcoholic Fatty Liver Disease
    Interventions
    Henagliflozein and Metformin; Linagliptin and Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-06
    Completion
    2026-11
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType2 Diabetes Mellitus; Nonalcoholic Fatty Liver Disease
    InterventionHenagliflozein and Metformin; Linagliptin and Metformin
    PhasePhase 4
    Registry statusRecruiting

  • Semaglutide and Vascular Regeneration

    NCT05870462 · start 2023-04-29

    Registered record
    Registry ID
    NCT05870462
    Conditions
    Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Obesity
    Interventions
    Semaglutide Pen Injector
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-04-29
    Completion
    2024-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Obesity
    InterventionSemaglutide Pen Injector
    PhasePhase 4
    Registry statusUnknown

  • The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .

    NCT07247656 · start 2022-12-01

    Registered record
    Registry ID
    NCT07247656
    Conditions
    Diabete Mellitus
    Interventions
    (Empagliflozin 10 mg+ Tab Linagliptin 5mg); Tab Empagliflozin 10 mg + Tab Metformin 500 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-12-01
    Completion
    2023-05-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabete Mellitus
    Intervention(Empagliflozin 10 mg+ Tab Linagliptin 5mg); Tab Empagliflozin 10 mg + Tab Metformin 500 mg
    PhasePhase 4
    Registry statusCompleted

  • Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes

    NCT05641337 · start 2022-10-01

    Registered record
    Registry ID
    NCT05641337
    Conditions
    Liver Cirrhosis; Diabetes
    Interventions
    Insulin Degludec and Insulin Aspart
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2022-10-01
    Completion
    2025-12-30
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis; Diabetes
    InterventionInsulin Degludec and Insulin Aspart
    PhasePhase 3
    Registry statusUnknown

  • Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects

    NCT05956522 · start 2022-07-01

    Registered record
    Registry ID
    NCT05956522
    Conditions
    Healthy
    Interventions
    Test Empagliflozin And Linagliptin Tablets; Reference Empagliflozin And Linagliptin tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-07-01
    Completion
    2023-01-13
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTest Empagliflozin And Linagliptin Tablets; Reference Empagliflozin And Linagliptin tablets
    PhasePhase 1
    Registry statusCompleted

  • Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus

    NCT05130463 · start 2022-03-22

    Registered record
    Registry ID
    NCT05130463
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Empagliflozin/Linagliptin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-03-22
    Completion
    2024-07-08
    Enrolment
    1,053

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionEmpagliflozin/Linagliptin
    PhaseNot recorded
    Registry statusCompleted

  • GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial

    NCT04796428 · start 2021-06-30

    Registered record
    Registry ID
    NCT04796428
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Canagliflozin; Dapagliflozin; Empagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-06-30
    Completion
    2023-12-31
    Enrolment
    1,167

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionCanagliflozin; Dapagliflozin; Empagliflozin
    PhasePhase 4
    Registry statusUnknown

  • The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2

    NCT04970940 · start 2020-07-02

    Registered record
    Registry ID
    NCT04970940
    Conditions
    T2DM (Type 2 Diabetes Mellitus)
    Interventions
    Treatment A; Treatment B; Treatment C
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-07-02
    Completion
    2020-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionT2DM (Type 2 Diabetes Mellitus)
    InterventionTreatment A; Treatment B; Treatment C
    PhasePhase 1
    Registry statusCompleted

  • The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects

    NCT05066516 · start 2020-06-25

    Registered record
    Registry ID
    NCT05066516
    Conditions
    Diabetes Mellitus
    Interventions
    FCDP, dapagliflozin 10mg/linagliptin 5 mg or co-administration of a single dose of dapagliflozin and linagliptin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-06-25
    Completion
    2020-10-18
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus
    InterventionFCDP, dapagliflozin 10mg/linagliptin 5 mg or co-administration of a single dose of dapagliflozin and linagliptin
    PhasePhase 1
    Registry statusCompleted

  • Compare Serum Klotho Levels in Patients on Oral Antidiabetic Treatment

    NCT03585777 · start 2018-10-11

    Registered record
    Registry ID
    NCT03585777
    Conditions
    Compare Serum Level of Klotho in Patients on Oral Antidiabetic Treatment
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-10-11
    Completion
    2019-03
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCompare Serum Level of Klotho in Patients on Oral Antidiabetic Treatment
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills

    NCT03629054 · start 2018-08-27

    Registered record
    Registry ID
    NCT03629054
    Conditions
    Healthy
    Interventions
    Empagliflozin, Metformin HCl, Linagliptin (fixed dose combination); Empagliflozin; Linagliptin; Metformin HCl
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-08-27
    Completion
    2018-11-05
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionEmpagliflozin, Metformin HCl, Linagliptin (fixed dose combination); Empagliflozin; Linagliptin; Metformin HCl
    PhasePhase 1
    Registry statusCompleted

  • Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

    NCT03429543 · start 2018-03-20

    Registered record
    Registry ID
    NCT03429543
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Metformin; Insulin; Placebo; Linagliptin; Empagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-03-20
    Completion
    2023-05-31
    Enrolment
    175

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionMetformin; Insulin; Placebo; Linagliptin +1 more
    PhasePhase 3
    Registry statusCompleted